Protalix BioTherapeutics (PLX) Cost of Revenue (2010 - 2026)

Protalix BioTherapeutics has reported Cost of Revenue for 17 years, with the latest figure at $4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 49.55% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $22.9 million (down 23.27% YoY), and the FY2025 full-year result was $27.0 million, up 11.0% from the prior year.
• Cost of Revenue for Q1 2026 stood at $4.1 million, down from $4.6 million in the prior quarter.
• The five-year high for Cost of Revenue was $9.5 million in Q2 2024, with the low at $2.4 million in Q4 2022.
• Average Cost of Revenue over 5 years is $5.8 million, with a median of $5.9 million recorded in 2025.
• Year-over-year, Cost of Revenue soared 269.46% in 2023 and plunged 56.12% in 2024.
• Tracing PLX's Cost of Revenue over 5 years: stood at $2.4 million in 2022, then soared by 269.46% to $8.9 million in 2023, then sank by 56.12% to $3.9 million in 2024, then grew by 18.86% to $4.6 million in 2025, then fell by 10.65% to $4.1 million in 2026.
• The last three Cost of Revenue figures came in at $4.1 million (Q1 2026), $4.6 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.

Peer Comparison